Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
s-KL
- Development stage
- Preclinical
- Lead developer
- Anew Medical
- Modality
- Cell Therapies, Recombinant Proteins and Enzymes, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies
- Administration
- Injection, Intracerebroventricular
01
Overview
s-KL (secreted Klotho) is a secreted isoform of the alphaKlotho protein, an aging suppressor. It is a 70 kDa protein that exerts pleiotropic beneficial properties by modulating insulin, insulin-like growth factor-1 (IGF-1), and Wnt signaling pathways, while also reducing inflammatory and oxidative stress. It has demonstrated therapeutic potential in preclinical models for enhancing remyelination by oligodendrocytes in multiple sclerosis, improving physical fitness, bone microstructure, and cognitive functions in aging, and inhibiting osteogenic differentiation in renal interstitial biomineralization. Delivery methods explored include adeno-associated virus (AAV) vectors and mesenchymal stem cells (MSCs) transduced with s-KL.
- Other names
- secreted klothosoluble klothosecreted isoform KlothoalphaKlotho isoform
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)FGF23 (Fibroblast growth factor 23)TRPV (TRPV channel family)Wnt (Wnt ligand)TGFBR2 (TGF-β receptor type 2)KCNJ1 (Kir1.1)
Beyond the preview
Go deeper on s-KL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on s-KL.